Dudediligence.

Crescent Biopharma, Inc

CBIONASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$279,103

4 notices · 16,003 sh

Oct 2025 to Oct 2026

Reported ·

$1,226,126

7 sales · 1 buy · $18.2M bought

Oct 2025 to Jun 2026

The two figures cover different periods.

All 7 reported sales carry the 10b5-1 box. Together they are 0.18% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-09-18: Joshua T Brumm, Form 1442026-09-18: Jonathan McNeill, Form 1442026-09-16: Jonathan McNeill, Form 1442026-09-16: Joshua T Brumm, Form 1442025-12-04: Harwin Peter Evan, bought2026-06-22: Brumm Joshua T, sold2026-06-22: McNeill Jonathan, sold2026-06-22: Im Ellie Eunkyung, sold2026-06-22: Bispham Barbara Harlin, sold2026-06-22: Scalzo Richard William, sold2026-06-22: Pinkas Jan, sold2026-06-22: Lynch Ryan, sold
under a no plan named▼ sale▲ buysize is dollars

Form 144 notices, newest first

2026-09-18Joshua T Brumm, Chief Executive Officer$154,843
9,013 shplan 2026-02-28Form 4s on file end Jun 23144 ↗
2026-09-18Jonathan McNeill, President and COO$75,850
4,415 shplan 2026-02-25Form 4s on file end Jun 23144 ↗
2026-09-16Jonathan McNeill, President and COO$15,115
804 shplan 2026-02-25Form 4s on file end Jun 23144 ↗
2026-09-16Joshua T Brumm, Chief Executive Officer$33,295
1,771 shplan 2026-02-28Form 4s on file end Jun 23144 ↗